Nigeria has received the first supply of Lenacapavir, a long-acting injection for HIV prevention, marking a major step in the country’s efforts to reduce new infections.
The medication’s arrival was approved by the Coordinating Minister of Health and Social Welfare, Ali Pate, with support from the Global Fund, reinforcing Nigeria’s commitment to expanding innovative HIV prevention strategies.
Lenacapavir is designed for pre-exposure prophylaxis (PrEP) and provides an alternative to daily oral HIV prevention drugs. Unlike daily pills, the injectable is administered twice a year, offering a more convenient option for people at risk of HIV infection.
Health experts say the long-acting injection could significantly improve treatment adherence and access, particularly among individuals who struggle to maintain daily medication schedules.
The National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme (NASCP), Adebobola Bashorun, said the delivery of the drug highlights Nigeria’s commitment to adopting evidence-based innovations to accelerate progress toward controlling the HIV epidemic.
According to him, expanding prevention options and strengthening service delivery will help reduce new infections and improve health outcomes across the country.
Bashorun added that NASCP, working with partners and stakeholders, will ensure the safe rollout and effective integration of Lenacapavir into national HIV prevention programmes.
Lenacapavir is expected to be available in Nigeria and 119 other low- and middle-income countries at an estimated annual cost of about $40 per person, following voluntary licensing agreements with generic manufacturers.